Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (531-540 of 754) with videos related to

Pageof 76
Sort By:
The New England Journal of Medicine|November 27, 2009
A sensitive cardiac troponin T assay in stable coronary artery diseaseTorbjørn Omland, James A de Lemos, Marc S Sabatine, et al.
American Heart Journal|August 10, 2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)Shelby D Reed, Jasmina I Radeva, Kevin P Weinfurt, et al.
Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
American Heart Journal|October 11, 2011
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or bothAmil M Shah, Chung-Lieh Hung, Sung Hee Shin, et al.
JACC. Heart Failure|April 11, 2021
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMuthiah Vaduganathan, Jonathan W Cunningham, Brian L Claggett, et al.
European Journal of Heart Failure|October 23, 2024
Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trialsHenri Lu, Brian L Claggett, Milton Packer, et al.
Circulation. Heart Failure|June 22, 2019
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
American Heart Journal|October 8, 2005
Prognostic use of echocardiography 1 year after a myocardial infarctionHicham Skali, Leonardo A M Zornoff, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|April 17, 2026
Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart FailureYasuhiro Hamatani, Brian L Claggett, Akshay S Desai, et al.
ESC Heart Failure|December 24, 2022
Potassium reduction with sodium zirconium cyclosilicate in patients with heart failureJean-Claude Tardif, Jean Rouleau, Glenn M Chertow, et al.
Pageof 76

Showing results (531-540 of 754) with videos related to

Sort By:
Pageof 76
The New England Journal of Medicine|November 27, 2009
A sensitive cardiac troponin T assay in stable coronary artery diseaseTorbjørn Omland, James A de Lemos, Marc S Sabatine, et al.
American Heart Journal|August 10, 2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)Shelby D Reed, Jasmina I Radeva, Kevin P Weinfurt, et al.
Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
American Heart Journal|October 11, 2011
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or bothAmil M Shah, Chung-Lieh Hung, Sung Hee Shin, et al.
JACC. Heart Failure|April 11, 2021
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMuthiah Vaduganathan, Jonathan W Cunningham, Brian L Claggett, et al.
European Journal of Heart Failure|October 23, 2024
Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trialsHenri Lu, Brian L Claggett, Milton Packer, et al.
Circulation. Heart Failure|June 22, 2019
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
American Heart Journal|October 8, 2005
Prognostic use of echocardiography 1 year after a myocardial infarctionHicham Skali, Leonardo A M Zornoff, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|April 17, 2026
Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart FailureYasuhiro Hamatani, Brian L Claggett, Akshay S Desai, et al.
ESC Heart Failure|December 24, 2022
Potassium reduction with sodium zirconium cyclosilicate in patients with heart failureJean-Claude Tardif, Jean Rouleau, Glenn M Chertow, et al.
Pageof 76